Jaguar Health, Inc.
JAGXCIK 0001585608 · Pharmaceutical Preparations · Nasdaq
- Jaguar Animal Health, Inc. (until 2017-07-31)
Revenue (TTM)
—
Q1 Mar 2026
Net Income (TTM)
−$40.23M
−136,396.8% YoY
Q1 Mar 2026
EPS Diluted (TTM)
−$614.59
+82.4% YoY
Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
—
Q1 Mar 2026
Net Margin
—
Q1 Mar 2026
Free Cash Flow (TTM)
−$15.58M
Q1 Mar 2026
Cash
$7.28M
Q1 Mar 2026
Total Debt
$10.77M
Q1 Mar 2026
Shares Outstanding
171.35M sh
Q1 Mar 2026
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.
Balance Sheet
Cash vs Debt
Latest news
All news →-
High Negative
Jaguar Health (JAGX) Exchanges Preferred Stock for 34,798 Common Shares
Jaguar Health swaps 3.8 shares of Series Q Preferred Stock held by Streeterville Capital for newly issued common shares, reducing preferred stock outstanding.